{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:03:58Z","timestamp":1781953438680,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1136\/ijgc-2023-004342","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T11:40:21Z","timestamp":1691754021000},"page":"1440-1447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Secondary cytoreduction in platinum sensitive relapsed ovarian cancer: an individual patient level meta-analysis"],"prefix":"10.1016","volume":"33","author":[{"given":"Seema","family":"Gulia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhana","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushmita","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6742-6378","authenticated-orcid":false,"given":"Sudeep","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004342_bb0010","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004342_bb0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2023-004342_bb0020","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomised trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004342_bb0025","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdn591","article-title":"The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer","volume":"20","author":"Oksefjell","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004342_bb0030","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1245\/s10434-006-9273-8","article-title":"Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer","volume":"14","author":"Benedetti Panici","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2023-004342_bb0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijsu.2016.12.031","article-title":"Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: a prognostic analysis with 103 cases","volume":"38","author":"Fan","year":"2017","journal-title":"Int J Surg"},{"key":"10.1136\/ijgc-2023-004342_bb0040","unstructured":"National Comprehensive Cancer Network (NCCN) . Guidelines for ovarian cancer including fallopian tube cancer and primary peritoneal cancer, version 1.2020. Available: http:\/\/www.nccn.org [Accessed 14 Dec 2021]."},{"key":"10.1136\/ijgc-2023-004342_bb0045","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","volume":"2013","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ijgc-2023-004342_bb0050","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004342_bb0055","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004342_bb0060","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, ramndomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004342_bb0065","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1245\/s10434-020-09226-7","article-title":"The role of secondary cytoreductive surgery in recurrent ovarian cancer: a systematic review and meta-analysis","volume":"28","author":"Marchetti","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2023-004342_bb0070","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-021-00842-9","article-title":"The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis","volume":"14","author":"Ding","year":"2021","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2023-004342_bb0075","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1177\/1536867X1801700402","article-title":"Reconstructing time-to-event data from published Kaplan\u2013Meier curves","volume":"17","author":"Wei","year":"2017","journal-title":"Stata J"},{"key":"10.1136\/ijgc-2023-004342_bb0080","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.11777","article-title":"Evaluation of 1-year vs shorter durations of adjuvant trastuzumab among patients with early breast cancer: an individual participant data and trial-level meta-analysis","volume":"3","author":"Gulia","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1136\/ijgc-2023-004342_bb0085","unstructured":"A Rohatgi . Web plot Digitalizer: Html5 based online tool to extract numerical data from plot images. version 4.2. Available: https:\/\/automeris.io\/WebPlotDigitizer\/ [Accessed 28 Jan 2022]."},{"key":"10.1136\/ijgc-2023-004342_bb0090","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1136\/ijgc-2023-004342_bb0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1136\/ijgc-2023-004342_bb0100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1136\/ijgc-2023-004342_bb0105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1136\/ijgc-2023-004342_bb0110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004342_bb0115","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2017.02.010","article-title":"A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer","volume":"145","author":"Cowan","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004342_bb0120","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000159266","article-title":"A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET\/CT and staging laparoscopy","volume":"75","author":"Fagotti","year":"2008","journal-title":"Oncology"},{"key":"10.1136\/ijgc-2023-004342_bb0125","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1245\/s10434-014-4011-0","article-title":"Positron emission tomography-laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer","volume":"22","author":"Fanfani","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2023-004342_bb0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/ijgc-2022-003904","article-title":"Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer","volume":"33","author":"Conte","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004342_bb0135","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2023-004342_bb0140","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2023-004342_bb0145","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (Solo2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004342_bb0150","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004342_bb0155","article-title":"Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis","volume":"7","author":"Gulia","year":"2022","journal-title":"ESMO Open"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24016797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24016797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:28:57Z","timestamp":1753234137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24016797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1048891X24016797"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004342","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary cytoreduction in platinum sensitive relapsed ovarian cancer: an individual patient level meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}